APA (7th ed.) Citation

X, W., SM, D., M, G., JV, N., BGC, L., K, L., . . . MJ, C. (2025). Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity. PLoS pathogens, 21(9), e1013468. https://doi.org/10.1371/journal.ppat.1013468

Chicago Style (17th ed.) Citation

X, Wu, et al. "Divergent Resistance Pathways Amongst SARS-CoV-2 PLpro Inhibitors Highlight the Need for Scaffold Diversity." PLoS Pathogens 21, no. 9 (2025): e1013468. https://doi.org/10.1371/journal.ppat.1013468.

MLA (9th ed.) Citation

X, Wu, et al. "Divergent Resistance Pathways Amongst SARS-CoV-2 PLpro Inhibitors Highlight the Need for Scaffold Diversity." PLoS Pathogens, vol. 21, no. 9, 2025, p. e1013468, https://doi.org/10.1371/journal.ppat.1013468.